

Last Day for Exercise of Warrants TO 2 in Scandinavian Real Heart AB

Scandinavian Real Heart AB ("Realheart" or the "Company") reminds holders of warrants of series TO 2 (the "warrants") that the last day for exercise is January 31, 2025. Holders who do not exercise their warrants risk that they expire without value.

Upon full exercise of all warrants, the Company will receive approximately SEK 1.4 million before issue costs. To avoid the warrants expiring without value, the holder must either trade or subscribe.

Important Dates

Last day of trading: January 29, 2025
Last day to exercise: January 31, 2025

Summarized Terms and Conditions

- **Subscription price:** SEK 8.47 per share (corresponding to 70 percent of the volume weighted average price during the measurement period).
- Exercise ratio: 200 warrants entitle the holder to subscribe for one (1) new share in the Company.
- ISIN code for the warrants: SE0020358166.
- **Total number of warrants:** 33,495,885 warrants series TO 2. Upon full exercise, 167,479 new shares will be issued.
- Dilution effect at full exercise: Approximately 7.5 percent.
- **Trading venue:** The warrants are admitted to trading on Nasdaq First North under the ticker "HEART TO2".


Instructions for use

Nominee-Registered Holdings

Holders with warrants in a share depository account, ISK account or endowment insurance should contact their bank or nominee well in advance of January 31, 2025, to ensure that the application is processed correctly.

Directly Registered Holdings

Holders with warrants in a securities account must complete and submit the application form for exercise, so that it is received by the issuing institution Nordic Issuing no later than January 31, 2025. The application form is available on the Company's and Nordic Issuing's respective websites.





Subscribed and paid shares may be registered in the subscriber's securities depository account as interim shares (IA) until the issue has been registered with the Swedish Companies Registration Office, whereupon interim shares are automatically converted into shares in Realheart.

Full Terms and Conditions of the Warrants

Full terms and conditions of the warrants are available on the Company's website, https://realheart.se/

Advisors

Skills Corporate Finance AB is the financial advisor to the Company and Setterwalls Advokatbyrå AB is the legal advisor. Nordic Issuing acts as issuing agent in connection with the exercise of the warrants.

For more information, please contact:

Ina Laura Perkins, CEO Phone: +46 (0) 70 406 49 21

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

About Us

Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trial models ahead of a first clinical study in patients. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se